Biosimilars are a promising option that might expand access to retinal therapies, reducing costs and improving real-world treatment outcomes as a result.
In July, the first FDA-approved biosimilar for an ophthalmic indication reached the market. Byooviz (ranibizumab-nuna, Biogen/Samsung Bioepis) is a biosimilar referencing Lucentis (ranibizumab, Genentech), indicated for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion (RVO) and myopic choroidal neovascularization.
“It is a test balloon for us to understand how the regulatory